Skip to main content

Insulet Corporation (PODD) Stock Analysis

Buy WaitModerate Confidence

Healthcare · Medical Devices

Wait — supporting gate not met yet. Price is at or below entry $167.43 but below 200-day MA (death cross); weak momentum still blocks BUY_NOW. Key risks: Concentration risk — Customer: Distributor A, Distributor B, Distributor C; Concentration risk — Product: Omnipod product platform.

Insulet develops, manufactures, and sells the Omnipod tubeless insulin delivery system for people with insulin-dependent diabetes in 25 countries, alongside drug delivery pods for Amgen's Neulasta. Revenue is primarily from Omnipod pods and PDMs sold through wholesalers and... Read more

$150.86+48.4% A.UpsideScore 6.7/10#2 of 40 Medical Devices
QualityF-score9 / 9FCF yield2.37%
Entry $167.43(Support Atr Sticky)Stop $151.22Target $222.11(analyst − 10%)A.R:R 4.4:1
Analyst target$246.79+63.6%24 analysts
$222.11our TP
$150.86price
$246.79mean
$360

Wait — supporting gate not met yet. Price is at or below entry $167.43 but below 200-day MA (death cross); weak momentum still blocks BUY_NOW. Key risks: Concentration risk — Customer: Distributor A, Distributor B, Distributor C; Concentration risk — Product: Omnipod product platform. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Growth is cheap relative to earnings, but the chart hasn't confirmed yet (PEG 1.14, quality 7.6/10, growth 10.0/10). Score 6.7/10, moderate confidence.

Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on death cross (50MA < 200MA). Suitability: moderate.

Val6.0Qual7.6Grw10.0Mom4.9Sent7.9Ins5.3Peer5.0Tech5.3Risk6.16.7OVERALL

Recent Developments — Insulet Corporation

Latest news

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards
V7 quality resilience bonus: +0.2 (Q=7.6 in RISK_OFF)
Sector modifier (Healthcare): +0.5
Strong earnings beat streak (4/4)
Risks
Concentration risk — Customer: Distributor A, Distributor B, Distributor C
Concentration risk — Product: Omnipod product platform
Below 200-MA, MA slope -6.2%/30d (confirmed downtrend)

Key Metrics

P/E (TTM)36.1
P/E (Fwd)19.2
Mkt Cap$10.7B
EV/EBITDA18.7
Profit Mgn10.4%
ROE23.0%
Rev Growth33.9%
Beta1.20
DividendNone
Rating analysts34

Quality Signals

Piotroski F9/9MoatWideCompounder✓

Options Flow

P/C0.74neutral
IV50%normal
Max Pain$320+112.1% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHCustomerDistributor A, Distributor B, Distributor C
    10-K Item 1: 'Distributor A| 27%| | 28%| | 28% Distributor B| 26%| | 26%| | 24% Distributor C| 25%| | 21%| | 19%'
  • HIGHProductOmnipod product platform
    10-K Item 1A: 'We expect to continue to derive nearly all our revenue from our Omnipod product platform'
  • MEDIUMcounterpartyAmgen Neulasta Onpro
    10-K Item 1A: 'Substantially all of our commercialized Drug Delivery revenue consists of sales of a customized version of our product for use in Amgen’s Neulasta Onpro kit under an agreement that expires in December 2028'

Material Events(8-K, last 90d)

  • 2026-02-24Item 4.01HIGH
    Insulet dismissed Grant Thornton LLP (GT) as independent auditor after completion of fiscal year ended December 31, 2025 audit. PricewaterhouseCoopers LLP (PwC) selected as auditor for fiscal year ending December 31, 2026. No disagreement cited.
    SEC filing →
  • 2026-03-04Item 5.02LOW
    Insulet entered into severance agreement and release dated February 27, 2026 with Ana M. Chadwick, former CFO. No material terms differ from previously disclosed Executive Severance Plan. Original departure disclosed September 2025.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 ceiling hit

GatesDeath cross (50MA < 200MA)Momentum 4.9<5.5 (soft — BUY_NOW allowed but watch)Momentum 4.9>=4.5A.R:R 4.4 ≥ 1.5Insider activity: OKNo SEC red flagsEARNINGS PROXIMITY 78d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Moderate
RSI
35 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $145.59Resistance $194.27

Price Targets

$151
$167
$222
A.Upside+47.2%
A.R:R4.4:1

Position Sizing

ConvictionHigh conviction
Suggested %0.6%
Max %1.2%
RegimeRisk-Off

Risk Alerts

! Death cross — 50-day MA below 200-day MA

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-08-06 (78d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is PODD stock a buy right now?

Wait — supporting gate not met yet. Price is at or below entry $167.43 but below 200-day MA (death cross); weak momentum still blocks BUY_NOW. Key risks: Concentration risk — Customer: Distributor A, Distributor B, Distributor C; Concentration risk — Product: Omnipod product platform. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Growth is cheap relative to earnings, but the chart hasn't confirmed yet (PEG 1.14, quality 7.6/10, growth 10.0/10). Target $222.11 (+47.2%), stop $151.22 (−-0.2%), Setup A.R:R 8.6:1. Score 6.7/10, moderate confidence.

What is the PODD stock price target?

Take-profit target: $222.11 (+48.4% upside). Target $222.11 (+47.2%), stop $151.22 (−-0.2%), Setup A.R:R 8.6:1. Stop-loss: $151.22.

What are the risks of investing in PODD?

Concentration risk — Customer: Distributor A, Distributor B, Distributor C; Concentration risk — Product: Omnipod product platform; Below 200-MA, MA slope -6.2%/30d (confirmed downtrend).

Is PODD overvalued or undervalued?

Insulet Corporation trades at a P/E of 36.1 (forward 19.2). TrendMatrix value score: 6.0/10. Verdict: Buy (Wait for Entry).

What do analysts say about PODD?

34 analysts cover PODD with a consensus score of 4.2/5. Average price target: $247.

What does Insulet Corporation do?Insulet develops, manufactures, and sells the Omnipod tubeless insulin delivery system for people with...

Insulet develops, manufactures, and sells the Omnipod tubeless insulin delivery system for people with insulin-dependent diabetes in 25 countries, alongside drug delivery pods for Amgen's Neulasta. Revenue is primarily from Omnipod pods and PDMs sold through wholesalers and distributors globally; three distributors each accounted for 25-27% of 2025 total revenues.

Related stocks: GMED (Globus Medical, Inc.) · BSX (Boston Scientific Corporation) · DXCM (DexCom, Inc.) · ZBH (Zimmer Biomet Holdings, Inc.) · LIVN (LivaNova PLC)